Mechanisms of Anti-Cancer Action and Pharmacology of Clofarabine

Anna Zhenchuk, Koroush Lotfi, Gunnar Juliusson, Freidoun Albertioni

► To cite this version:

Anna Zhenchuk, Koroush Lotfi, Gunnar Juliusson, Freidoun Albertioni. Mechanisms of Anti-Cancer Action and Pharmacology of Clofarabine. *Biochemical Pharmacology*, 2009, 78 (11), pp.1351. 10.1016/j.bcp.2009.06.094 . hal-00524463

HAL Id: hal-00524463

<https://hal.science/hal-00524463>

Submitted on 8 Oct 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript

Title: Mechanisms of Anti-Cancer Action and Pharmacology of Clofarabine

Authors: Anna Zhenchuk, Koroush Lotfi, Gunnar Juliusson, Freidouh Albertioni

PII: S0006-2952(09)00564-4
DOI: doi:10.1016/j.bcp.2009.06.094
Reference: BCP 10241

To appear in: *BCP*

Received date: 15-4-2009
Revised date: 21-6-2009
Accepted date: 23-6-2009

Please cite this article as: Zhenchuk A, Lotfi K, Juliusson G, Albertioni F, Mechanisms of Anti-Cancer Action and Pharmacology of Clofarabine , *Biochemical Pharmacology* (2008), doi:10.1016/j.bcp.2009.06.094

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Review

Mechanisms of Anti-Cancer Action and Pharmacology of Clofarabine

^aAnna Zhenchuk, ^bKoroush Lotfi, ^cGunnar Juliusson and ^aFreidoun Albertioni

^a*Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institute, Karolinska Hospital, SE-171 76 Stockholm;* ^b*Department of Medicine and Care, Clinical Pharmacology, Faculty of Health Sciences, Linköping University;* ^c*Department of Hematology, University Hospital, SE-581 85 Linköping; and* ^c*Lund Strategic Center for Stem Cell Biology and Therapy, Dept. of Hematology, Lund University Hospital, SE-221 84 Lund, Sweden.*

Keywords:

Clofarabine
Nucleoside analogues
Deoxycytidine kinase
Ribonucleotide reductase
Apoptosis
Resistance to antimetabolites
Pharmacokinetics
Leukemias

Abbreviations:

ADA – adenosine deaminase
ALL – acute lymphoblastic leukemia
AML – acute myeloid leukemia
AraC – cytarabine
CAFda – clofarabine
CdA – cladribine

1
2 *CLL* – chronic lymphocytic leukemia
3 *dCK* – deoxycytidine kinase
4 *dGK* – deoxyguanosine kinase
5 *DLT* – dose limiting toxicity
6 *FaraA* – fludarabine
7 *HSA* – human serum albumin
8 *MTD* – maximum tolerated dose
9 *RR* – ribonucleotide reductase
10 *Vdss* – volume of distribution at steady state
11 *WBC* – white blood cell
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5 ABSTRACT
6
7

8 Clofarabine, a next-generation deoxyadenosine analogue, was developed on the
9
10 basis of experience with cladribine and fludarabine in order to achieve higher
11
12 efficacy and avoid extramedullary toxicity. During the past decade this is the only
13
14 drug granted approval for treatment of pediatric acute leukemia. Recent clinical
15
16 studies have established the efficacy of clofarabine in treating malignancies with a
17
18 poor prognosis, such as adult, elderly, and relapsed pediatric leukemia. The
19
20 mechanisms of its anti-cancer activity involve a combination of direct inhibition of
21
22 DNA synthesis and ribonucleotide reductase and induction of apoptosis. Due to
23
24 this broad cytotoxicity, this drug is effective against various subtypes of leukemia
25
26 and is currently being tested as an oral formulation and for combination therapy of
27
28 both leukemias and solid tumors. In this review we summarize current knowledge
29
30 pertaining to the molecular mechanisms of action and pharmacological properties
31
32 of clofarabine, as well as clinical experiences with this drug with the purpose of
33
34 facilitating the evaluation of its efficacy and the development of future therapies.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1. Introduction

Nucleoside analogues have had a substantial impact on the treatment of cancer, especially hematological malignancies. The most credible explanation is the dependency of hematopoietic cells on salvage synthesis of nucleosides [1] and their expression of several membrane transporters that take up nucleoside analogues [2]. Their structural similarity to physiological nucleosides allows these analogues to be taken up by cells, metabolized, and incorporated into DNA or RNA. Therefore, the main targets of these activated nucleoside analogues are the enzymes involved in *de novo* and salvage pathways of nucleoside synthesis.

The history of nucleoside analogues dates back to the late 1950s when cytosine arabinoside (cytarabine, AraC) was synthesized and subsequently became the backbone in the treatment of acute myeloid leukemia (AML) and one of the most widely used nucleoside analogues to date [3]. Single-dose treatment with AraC was not promising, but in combination with agents that interacted with topoisomerase, such as anthracyclines, a high rate of remission could be achieved in AML patients [4]. The success of AraC led to the development of other arabinosylpurine homologues (e.g. 9- β -D-arabinofuranosyladenine (araA)). Since the clinical activity of araA was found to be limited due to its rapid deamination

1
2 by adenosine deaminase (ADA) [5], ADA-resistant halogenated arabinosyl
3
4 derivatives such as 2-fluoro-9- β -arabinofuranosyladenine (fludarabine) were then
5
6 developed [6]. Thereafter, because of the insolubility of fludarabine, its 5'-
7
8 monophosphate derivative (fludarabine monophosphate, FaraA, Fludara[®]), was
9
10 designed for conversion into fludarabine aA by endogenous phosphatases.
11
12 However, treatment with this latter drug also results in the formation by
13
14 phosphorylase cleavage of 2-fluoroadenine, a toxic compound with only minor
15
16 antitumor activity [7]. In the early 1970s the realization that halogenated
17
18 analogues exert an anti-leukemic effect led to the synthesis of 2-
19
20 chlorodeoxyadenosine (cladribine, CdA) [8], which, however, has reduced oral
21
22 bioavailability due in part to its instability in the acidic gastric environment as
23
24 well as its susceptibility to enzymatic cleavage [9-11].
25
26
27
28
29
30
31
32
33

34
35 In the 1990s, in order to tackle all the above-mentioned limitations of early
36
37 nucleoside analogues, a next-generation deoxyadenosine analogue, clofarabine
38
39 (2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, CAFdA, Cl-F-ara-A), a 2'-
40
41 arabino-fluoro derivative of cladribine, was synthesized [12]. The rationale
42
43 behind its design was to combine the structural features of cladribine and
44
45 fludarabine (*Figure 1*). Like cladribine and fludarabine, clofarabine is toxic to
46
47 both non-proliferating human lymphocytes and rapidly proliferating cells, while
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

being resistant to phosphorylitic cleavage and deamination-stable in acidic environments.

Preclinical studies indicated a high degree of efficacy of clofarabine and subsequently lead to human clinical trials. In 2004 the FDA approved clofarabine (Clolar™, Genzyme) for the treatment of pediatric leukemic patients - a decision followed by European Commision approval in 2006 (Evoltra®, Bioenvision). Today the anti-cancer activity of clofarabine toward other types of tumors, as well as in other age groups, is being actively investigated.

2. Molecular mechanisms of action

2.1. Structure and physicochemical properties

Clofarabine was designed as an adenosine analogue with improved stability both in the plasma and the acidic gastric environment. And, indeed, the introduction of a fluorine atom at the 2'-arabino position of cladribine increases its stability at pH 1.0 [13]. As predicted, the pKa value of clofarabine (1.75) is higher than that of cladribine (1.28). Furthermore, it exhibits the highest lipophilicity among related purine analogues [13] and is resistant to degradation by *E. coli* nucleoside phosphorylase [14].

2.2. Transport and metabolism

Clofarabine metabolites are retained by cells to a greater extent than are metabolites of cladribine, which is believed to be one factor in the more pronounced anti-tumoral effect and higher hematological toxicity of the former [15]. Other factors contributing to its higher anti-cancer activity are thought to be clofarabine's high affinity for nucleoside transporters and deoxycytidine kinase (dCK), as well as for key enzymes involved in DNA synthesis, e.g. ribonucleotide reductase (RR) and DNA polymerase- α and - ϵ .

Most cells have two types of active nucleoside transporters: human equilibrative nucleoside transporter (hENT) and human concentrative nucleoside transporter (hCNT). Transport via hENTs is a sodium-independent mechanism involving primarily bi-directional facilitative diffusion driven by a gradient in the nucleoside concentration across the cell membrane. In contrast, the hCNTs are sodium-dependent active transporters that depend on ATP for their ability to transport purine nucleosides into the cell against a concentration gradient.

Clofarabine is believed to enter cells by both facilitated and active nucleoside transport mechanisms as well as, at higher concentrations and upon longer exposure, by passive diffusion across lipid membranes [16]. The

1
2 importance of membrane nucleoside transporters in clofarabine metabolism is
3
4 indicated by the fact that the rate of clofarabine uptake is ~10-fold higher by
5
6 transport-competent than transport-deficient human leukemia cells [16]. In
7
8 particular, cells expressing hCNT3 exhibit the highest rate of clofarabine uptake
9
10 compared to the cells expressing hCNT2, hENT1, and hENT2, whereas transport-
11
12 deficient and hCNT1-expressing cells demonstrate no uptake, consistent with the
13
14 fact that hCNT1 is specific for pyrimidines. In addition, clofarabine was more
15
16 cytotoxic to cells expressing hENT1 than fludarabine or cladribine.
17
18
19
20
21
22
23

24 Upon entry into cells, clofarabine is phosphorylated to its monophosphate
25
26 derivatives, primarily by dCK, a constitutively expressed key cytosolic enzyme
27
28 involved in the salvage pathway of DNA synthesis, but also by the mitochondrial
29
30 enzyme deoxyguanosine kinase (dGK) [17]. Further intracellular phosphorylation
31
32 results in the final metabolite, clofarabine triphosphate. The cytotoxicity of
33
34 nucleoside analogues in quiescent cells (i.e. lymphocytes) depends mainly upon
35
36 selective and progressive accumulation of the triphosphate metabolites because of
37
38 the high ratio of dCK to cytosolic 5'-nucleotidase. The latter acts as a deactivator
39
40 of nucleoside analogues by dephosphorylating the triphosphate metabolites and
41
42 enabling their transport out of the cell. The importance of dCK for the efficacy of
43
44 clofarabine was confirmed by our recent finding that the cells deficient in this
45
46 activity are more resistant to the cytotoxic effect of this drug [18]. Furthermore,
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

the concentration of dCK is typically highest in lymphoid tissues, as well as considerably higher in tumor tissues than in normal tissues [19]. The studies with recombinant human dCK and kinases in the crude leukemic cell extracts have revealed that the efficiency ($V_{\max}/K_m$) of clofarabine phosphorylation by these enzymes is close to, or greater than, that of the natural substrate deoxycytidine, as well as significantly greater than that of cladribine or fludarabine [20, 21]. The interactions between 2-Cl and its surrounding hydrophobic residues contribute to the high catalytic efficiency of dCK for clofarabine [22].

Although dCK activity is rate-limiting for the accumulation of fludarabine triphosphates, this is not the case with clofarabine [15]. Accumulation of clofarabine appears to be determined by the rate of phosphorylation of its monophosphate to diphosphate by purine nucleotide monophosphate kinase, similarly to cladribine [15, 23]. One explanation might be that nucleoside analogues bearing a 2-chloroadenine nucleobase are relatively poor substrates for the monophosphate kinase.

2.3. Mechanisms of anti-cancer activity

The anti-cancer activity of clofarabine involves three major mechanisms: inhibition of DNA synthesis, inhibition of ribonucleotide reductase, and direct

1
2 induction of apoptosis (Figure 2). This broad range of activities explains the
3
4 efficacy of the drug against both rapidly growing and quiescent tumors [14].
5
6

7
8 Clofarabine competes potently with dATP for binding to DNA polymerase-
9
10 α and $-\epsilon$ [24]. At a low ratio of clofarabine triphosphate to dATP, clofarabine is
11
12 incorporated primarily into internal phosphodiester linkages inhibiting DNA
13
14 repair; whereas, at higher ratios, clofarabine is detected mainly at terminal sites
15
16 inhibiting DNA elongation [15]. The most pronounced inhibition of DNA
17
18 elongation is observed at clofarabine triphosphate to dATP ratios greater than one
19
20 [25]. Incorporation of clofarabine monophosphate into DNA impairs its
21
22 elongation and repair by causing chain termination and strand breaks. However,
23
24 clofarabine triphosphate is not a potent inhibitor of DNA polymerase- β ,
25
26 mitochondrial DNA polymerase- γ , or DNA primase [24].
27
28
29
30
31
32
33
34

35
36 In a recent article Chen and coworkers (2008) suggested that clofarabine
37
38 action may as well involve an RNA-directed mechanism. Clofarabine
39
40 triphosphates were shown to cause chain termination in the absence of ATP [26].
41
42
43 With increasing amounts of clofarabine triphosphates, there was a concentration-
44
45 dependent effect on polyadenylation due to blockage of the ability of yeast
46
47 poly(A)polymerase (yPAP) to extend the poly(A)-tail by the analogues'
48
49 incorporation into RNA [26].
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Besides DNA polymerase inhibition, clofarabine triphosphate potently inhibits RR activity (50% at 65 nM) [24] by binding to the allosteric site on the regulatory subunit, incorporating in this manner anti-cancer properties of fludarabine. Inhibition of RR depletes the dNTP pool, with the most pronounced reduction in the dCTP pool, followed by dATP and dGTP, and only a minor effect on the dTTP pool. Through depletion of the dNTP pool, clofarabine self-potentiates the incorporation of clofarabine triphosphates into DNA, thus explaining the increased effectiveness of clofarabine in DNA synthesis inhibition [27].

Furthermore, depletion of dNTP pools can lead to enhanced nucleoside kinase activity and thereby increased phosphorylation of nucleoside analogues, more pronounced accumulation and prolonged retention of the triphosphate metabolites, and, consequently, a more potent anti-cancer effect [25]. The damage caused by incorporation of clofarabine monophosphate into DNA initiates a chain of events that result in activation of pro-apoptotic pathways. Clofarabine can replace dATP and directly affects cytosolic apoptotic protease-activating factor-1 (APAF1), thus causing caspase activation [28, 29]. Clofarabine also directly affects mitochondria by altering the transmembrane potential and, as a result, releasing cytochrome c and apoptosis-inducing factor (AIF) [30]. Mitochondrial damage caused by clofarabine may be explained by direct binding of the

1
2 triphosphate metabolite to proteins in the mitochondrial membrane, leading to an
3
4 alteration in membrane potential as well as intra-mitochondrial accumulation of
5
6 this triphosphate [30]. The combined actions of cytochrome c, AIF, APAF-1, and
7
8 caspase-9 lead to the formation of the apoptosome complex responsible for
9
10 programmed cell death induction.
11
12
13
14
15

16 Moreover, clofarabine has been shown to induce dose- and time-dependent
17
18 down-regulation of the death suppressor proteins Bcl-X(L) and Mcl-1 and de-
19
20 phosphorylation of anti-apoptotic kinase Akt and its downstream effectors (Bad,
21
22 FKHRL1) [31]. An interesting observation was made in the T-ALL CEM cell
23
24 line when treated with clofarabine and caffeine [31]. The addition of caffeine
25
26 inhibited the down-regulation of Cdc25A, usually observed when cells are treated
27
28 with clofarabine alone, and increased the cleavage of PARP. Therefore, a
29
30 combinatorial effect on apoptosis could be expected if clofarabine is administered
31
32 together with inhibitors of chk1, a checkpoint homolog that phosphorylates
33
34 Cdc25 and prevents cells entering mitosis.
35
36
37
38
39
40
41
42
43
44
45

46 **2.4. Mechanism of resistance**

47
48
49
50
51

52 The effectiveness of nucleoside analogue treatment against cancer cells is
53
54 principally limited by the primary or acquired drug resistance. This commonly
55
56
57
58
59
60
61
62
63
64
65

happens due to alteration in the activity of one or more actors in the metabolic pathway of a drug, thus leading to its reduced effectiveness. A detailed knowledge of the molecular mechanisms underlying such resistance would enable the use of appropriate dosing schedules and combination therapies in the clinical setting to overcome this limitation.

There are few studies that have also initiated the investigations into potential mechanisms of resistance. In one such study, the resistance to clofarabine acquired by HL60 and CCRF-CEM cell lines is directly correlated with reduced activity of the nucleoside phosphorylating enzyme dCK, as has been previously found to be the case with cladribine [20, 32]. We detected dCK deficiency at the level of enzymatic activity, the protein level, and also as mRNA expression for the cell lines resistant to clofarabine; these cells did not consistently form detectable levels of clofarabine triphosphates. However, no mutations in the coding region of the dCK gene were detected. The suggestion that DNA methylation is responsible for the decreased level of dCK in resistant cancer cells has not been confirmed [32, 33].

The problem of resistance due to reduced dCK and/or dGK activity might be overcome by introducing the drug as a pro-nucleotide, thereby releasing the deoxynucleoside 5'-monophosphate directly into the cell. In addition, determination of dCK and/or dGK activities might help predict how well a patient

will respond to a certain cytotoxic drug and which dose and combination of drugs will be most effective.

Clofarabine-resistant cell lines showed cross-resistance to other antimetabolites (i.e. fludarabine, Ara-C, difluorodeoxycytidine, dfdc) phosphorylated by dCK [20, 32]. Thus, clofarabine-resistant cells also accumulate lower levels of cladribine and other analogue nucleotides. On the other hand, cells resistant to fludarabine exhibited cross-resistance to cladribine, but not clofarabine.

No alteration in nucleoside transport or expression of the classical MDR (multidrug-resistance) protein was detected in clofarabine-resistant cells, suggesting that the mechanism of acquired resistance to clofarabine is a specific, rather than a general, phenomenon [20, 32]. Clofarabine-resistant cells also exhibit the highest number of structurally rearranged chromosomes, indicating a high potential of clofarabine to rearrange the genome [32]. However, this was not the cause of dCK deficiency.

Expression of a small subunit of RR (R2) was substantially reduced and the enzyme's activity was halved with no alteration of allosteric activity in the clofarabine-resistant cell lines, as opposed to fludarabine-resistant cell lines, where RR was substantially higher than in the wild type cell line [32]. Since the resistant cell line with inhibited dCK and RR activity still produced dNTPs and

1
2 kept on proliferating, it was hypothesized that p53R2, a small subunit of RR
3
4 directly induced by p53, replaces R2 to form active ribonucleotide reductase. A
5
6 truncated form of p53R2 was detected that may replace R2 in the production of
7
8 dNTPs in the resistant cell lines.
9
10

11
12 Other mechanisms of resistance to clofarabine are thought to involve
13
14 changes in Ca^{2+} -sensitive mitochondrial phenomena and are probably not
15
16 influenced by the Fas pathway, as in the case of cladribine [34].
17
18
19
20
21
22
23

24 **3. Pharmacokinetics and anti-cancer activity**

25 **3.1. *In vitro* investigations**

26
27
28
29
30
31
32
33
34
35 As expected from its potent inhibition of DNA synthesis, clofarabine exerts
36
37 potent growth inhibition and cytotoxic activity (IC_{50} values = 0.028–0.29 μM) in
38
39 a wide variety of leukemia and solid tumor cell lines *in vitro* [35]. Thus, of 60
40
41 human tumor cell lines in the National Cancer Institute's Developmental
42
43 Therapeutics Program panel, clofarabine potently inhibits the growth (GI_{50} values
44
45 = < 0.0001–0.45 μM) of 35. The cell types sensitive to clofarabine include those
46
47 of non-small-cell lung, colon, central nervous system, melanoma, ovarian, renal,
48
49 prostate, and breast tumors [36].
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Cariveau and coworkers (2008) also demonstrated that clofarabine exhibits a strong radiosensitizing effect on murine tissues *in vitro* and *in vivo*, by interfering with the repair of DNA damage [37]. Another mechanism driving the radiosensitization activity of a combination of clofarabine with ionizing radiation (IR) was found to be the activation of dCK by IR, which consistently enhances clofarabine cytotoxicity [38].

In vitro exposure of mononuclear cells from chronic lymphocytic leukemia (CLL) and AML patients to identical concentrations of clofarabine and cladribine leads to higher intracellular accumulation of the former's triphosphate metabolites [20, 39]. In these cells, the major metabolite detected was clofarabine monophosphate, with clofarabine diphosphate representing less than 10% of the total nucleotide metabolite present, thereby confirming that dCK is not the rate-limiting step for the formation of clofarabine triphosphate. Interestingly, no correlation was found between the level of phosphorylated metabolites, enzymes (dCK, dGK), and the cytotoxicity of clofarabine, suggesting that additional factors determine its cytotoxic activity [39].

In isolated perfused rat liver, clofarabine and cladribine have a similar first-pass metabolism of 50% [40]. The rate of elimination of both of these substances is strongly dependent on the initial concentrations. However, the elimination rate of clofarabine is much slower and its concentration declines without an increase

1
2 in the concentration of the degradation product, 2-chloroadenine, most likely due
3
4 to the binding of clofarabine to components of hepatic tissue. The elimination
5
6 kinetics of clofarabine 5'-mono-, di-, and triphosphate exhibit tri-phasic behavior,
7
8 with a β -half-life of 8–24 hours and a very long γ -half-life (29 hours), indicating
9
10 prolonged cellular retention [15].
11
12
13
14
15

16 In a study on polarized human kidney proximal tubule cells (hRPTC11),
17
18 apical-to-basolateral fluxes of clofarabine as well as fludarabine and cladribine
19
20 across the cell layer were observed following mediation by the coupling of apical
21
22 hCNT3 to basolateral hENT2 [41]. Such directionality of transepithelial fluxes
23
24 of these three nucleoside analogues resembles that of adenosine, which is
25
26 reabsorbed in human kidney proximal tubules. These observations could explain
27
28 the delayed elimination of clofarabine. A deeper insight into the mechanisms of
29
30 hNTs transport of clofarabine could lead to strategies aimed at improving its
31
32 dosing with maximum efficacies and minimum toxicity.
33
34
35
36
37
38
39
40

41 The major metabolite detected in rat and dog hepatocytes after exposure to
42
43 clofarabine is P11, which accounts for 1.2% and 2.5%, respectively, of the total
44
45 radioactivity recovered [42]. P11 is suggested to be a carboxy- or methoxy-
46
47 clofarabine, but the exact location of the change remains unknown. The only
48
49 metabolite observed in the case of human hepatocytes is P14, which accounts for
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

0.2% of the total radioactivity recovered and has been suggested to be the sulfates' conjugate of clofarabine at the 5' carbon.

The *in vitro* efficacy of clofarabine was compared to those of nelarabine and AraC in a panel of acute lymphoblastic leukemia (ALL) cells [43]. The concentration of clofarabine that inhibits growth by 50% is 188 times lower than the corresponding concentration for nelarabine in all cases. Clofarabine appears to be marginally more effective in B-lineage than in T-lineage ALL and B-lineage is also several times more sensitive to clofarabine than AraC. There is a potential for cross-resistance of clofarabine to many ALL therapeutics, but not methotrexate or thiopurines. This distinct resistance profile may prove useful in combination with other compounds.

One such combination study was undertaken with alkylating agents and clofarabine or fludarabine in lymphocytes isolated from CLL patients [44]. DNA damage repair mechanisms were first initiated in the CLL lymphocytes by treatment with 4-hydroxycyclophosphamide. This DNA repair was then inhibited by DNA chain termination in an equivalent manner by treatment with either fludarabine or clofarabine. However, clofarabine triphosphates exhibited increased rates of intracellular accumulation, thus leading to maximal inhibition at 1/10 the concentration of fludarabine triphosphates.

Exposure to such agents as cladribine, clofarabine, fludarabine, or AraC leads to a 2–4-fold increase in dCK activity (most probably by direct inhibition of ribonucleotide reductase) in the HL-60 cell line, as well as in peripheral blood mononuclear cells [45]. This phenomenon has been exploited by treating cells with one deoxynucleoside analogue initially in order to induce dCK activity and thereafter administering a second analogue; and, as expected, clofarabine pretreatment to induce dCK enhances subsequent accumulation of AraC triphosphate in myeloid cell lines [46]. Similarly, pretreatment of HCT-116 colon, K562 leukemia, and RL lymphoma cell lines with clofarabine enhanced the metabolism of T-araC (1-beta-D: -[4-thio-arabinofuranosyl] cytosine), a new cytosine analogue with superior anti-cancer activity as compared to AraC [47].

Caution must be observed, however, when combining AraC with clofarabine since these compounds have been shown to have cross-resistance [48]. Alternatively, valproic acid (VPA), a histone deacetylase inhibitor used as a drug against epilepsy, exhibits a synergistic effect when combined with clofarabine in AML cell lines and primary cells. A possible explanation could be that VPA induces apoptosis by activating both extrinsic and intrinsic apoptotic pathways.

A recent study demonstrated the hypomethylation property of clofarabine in human lymphoid tumor cells as well as its ability to up-regulate the expressing

of cancer-testis (CT) antigens (Sp17 and SPAN-Xb) aberrantly expressed in tumor cells [49]. If the same property is proven to be effective *in vivo*, it could be possible to administer low-dose clofarabine to patients to up-regulate the expression of CT antigens to increase the susceptibility of the tumor cells to the cytotoxic effect of antigen-specific cytotoxic T cells prior to administering specific tumor vaccines targeting CT antigens. Furthermore, hypomethylating DNA clofarabine at low doses could potentially enhance the expression of tumor suppressor genes that are often hypermethylated, and thus inhibited, in cancer cells, leading to activation of pro-apoptotic genes.

Silencing of 5'-nucleotidase cNT1 by siRNA interference in a panel of leukemic cell lines has significantly augmented the cytotoxicity of clofarabine. This investigation could prove the combination of clofarabine nucleotidases inhibitors useful for cancer treatment [50].

3.2. *In vivo* investigations

In addition to numerous studies on the effects of clofarabine in cells, a considerable amount of *in vivo* data on various animal models is available.

The dose and schedule-dependent cancer activity of clofarabine was demonstrated by testing different dosing schedules in an NCI H460 lung tumor

1
2 murine model with the greatest anti-tumor activity seen when the daily
3
4 clofarabine dose was subdivided into three equal doses and administered at 4-
5
6
7 hour intervals each day for 30 days [36, 51].
8
9

10 Since nucleoside transporters are expressed in many tissues, clofarabine is
11
12 expected to be widely distributed in both tumor and normal tissues. Indeed, this
13
14 has been found to be the case in mice and rats, where the tissue distribution is
15
16 rapid and widespread with the highest concentrations occurring in highly perfused
17
18 organs [42, 52].
19
20
21
22
23

24 The tissue-to-plasma ratios of clofarabine in the liver and myocardium
25
26 were considerably high (4.8 and upward) [42]. This is most probably due to the
27
28 fact that the active clofarabine phosphates must be dephosphorylated in order to
29
30 be exported from the cell as well as to the lipophilicity of the parent drug. These
31
32 observations are consistent with pharmacokinetic studies which reveal that,
33
34 following intravenous administration, clofarabine is extensively distributed
35
36 throughout the body, with a volume of distribution at steady state (V_{dss}) of
37
38 approximately 1.4–2.6 L per kg in mice, 3.2–3.6 L per kg in rats, and 0.9–1.2 L
39
40 per kg in dogs [36].
41
42
43
44
45
46
47
48

49 Intravenous administration of [^{14}C]clofarabine 25 mg/kg/day to rats
50
51 confirmed the non-linear pharmacokinetics, showing three exponential phases of
52
53 elimination, with half-lives of 0.3, 1.3, and 12.8 hours [42]. Close to 80% of the
54
55
56
57
58
59
60
61
62
63
64
65

dose administered was recovered in the urine and 10% in the feces. The major metabolite, 6-ketoclofarabine, is believed to be formed extrahepatically via adenosine deaminase.

The fact that clofarabine is more stable in an acidic environment and more lipophilic than cladribine [13, 40] leads to the assumption that the former would have more side effects, particularly neurotoxicity. However, in mice, the accumulation of clofarabine in brain tissue was found to be lower than that of cladribine [52], contradicting the assumption that clofarabine's more pronounced lipophilicity would render it a more effective drug for the treatment of lymphoproliferative disorders in the central nervous system (CNS).

On the other hand, in a study of non-human primates, clofarabine was found to penetrate into the cerebrospinal fluid, although to a modest extent [53]. The concentrations obtained there may nevertheless approach those known to be cytotoxic *in vitro*.

A substantial anti-cancer effect has been observed against human colon tumors transplanted into nude mice, exhibiting schedule-dependent anti-tumor activity upon intraperitoneal, intravenous or, particularly, oral administration of clofarabine [54]. Fifty percent of tumor growth was inhibited at 0.26 μM in a 72-h exposure, a concentration significantly lower than that of fludarabine and

1
2 cladribine. The most effective of three administration regimens tested (single,
3
4
5 twice-weekly, 5-day once daily) was a 5-day daily administration schedule.
6

7
8 Administration of oral doses in rats equivalent to intravenous doses of 10
9
10 and 25 mg/kg provides bioavailability estimates of approximately 50%, indicating
11
12 the feasibility of oral treatment [55]. Approximately 83% of clofarabine was
13
14 recovered in plasma with only 13.3% binding to plasma proteins.
15
16
17

18
19 Orally administered clofarabine again showed superior anti-tumor activity
20
21 with regressive or cytostatic growth curves compared to intraperitoneally
22
23 administered clofarabine in an HT29 colon tumor mouse model [56].
24
25 Additionally, in an RL lymphoma tumor mouse model, prolonged administration
26
27 (21 days) of oral clofarabine showed markedly enhanced anti-tumor activity as
28
29 compared to intravenous administration on a daily $\times$ 5 days schedule, the dosing
30
31 regimen commonly used in clinical trials [57].
32
33
34
35
36
37

38
39 The hematological toxicity effects of clofarabine in Fischer 344 rats were
40
41 least severe, in terms of effects on the circulating white blood cell count (WBC),
42
43 when administered in daily oral doses of 36 and 60 mg/m² for 21 days than in
44
45 doses of 150 and 240 mg/m² administered orally or intravenously daily for
46
47 5 days. Intravenously dosed rats also exhibited decreased cellularity in the bone
48
49 marrow [57].
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2 In an attempt to further improve the pharmacological and toxicological
3 properties of clofarabine, Heckl-Östreicher and coworkers have synthesized an
4
5 EPD-clofarabine prodrug, which is activated by membrane-associated specific
6
7 hydrolases releasing the free nucleoside into the respective cells [58]. In a
8
9 comparative pharmacokinetic study, a prodrug revealed a 36 times higher plasma
10
11 exposure and an increased terminal half-life but very low free clofarabine
12
13 concentrations. EPD-clofarabine showed high efficacy in a variety of solid tumor
14
15 xenograft models, demonstrating improved tolerability and increased and
16
17 sustained anti-tumoral growth inhibition compared to clofarabine. Furthermore,
18
19 this compound could be a potential candidate for the treatment of pancreatic
20
21 cancer as monotherapy or in combination with gemcitabine as well as in the
22
23 gemcitabine-resistant form of pancreatic cancer [59].
24
25
26
27
28
29
30
31
32
33

34
35 In summary, the *in vivo* studies demonstrated clofarabine to be an effective
36
37 drug with a substantial anti-cancer effect and superior oral bioavailability, as well
38
39 as a very promising candidate for combination therapies, thus successfully
40
41 highlighting its potential in human studies.
42
43
44
45
46
47
48

49 3.3. Pharmacokinetic data in humans

50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

The initial studies in humans have corroborated the potent nature of clofarabine as an anticancer agent observed in animal studies. A consistent decline has been observed (68–99%) in the WBC count in all acute leukemia patients treated with 40 mg/m² of clofarabine after 5 days, indicating its high potency [60].

DNA synthesis is inhibited by 75–95% at the end of an infusion of clofarabine at doses ranging from 22.5 to 55 mg/m². In the lower dose (22.5 and 30 mg/m²) range a partial recovery of the inhibition of DNA synthesis was observed after 24 hours, while at the higher doses (40 and 55 mg/m²) this inhibition remained unchanged. This implies that there is a dose-dependent effect on the maintenance of inhibition of DNA synthesis by clofarabine treatment [60]. Specifically, the decrease in DNA synthesis was shown to be associated with the accumulation of clofarabine triphosphates in the blasts of adults with refractory leukemias [60, 61].

Bonate and coworkers (2004) have analyzed pharmacokinetic data from one Phase I [62] and two Phase II studies [63]. Weight and WBC count were the only patient-specific factors identified as being important for the pharmacokinetics of clofarabine [64]. However, in a study conducted by the Genzyme Corporation in adults with advanced solid refractory tumors, neither clofarabine clearance nor clofarabine central volume correlated with weight or body surface area [56].

Clofarabine demonstrated a β -half-life of 6.4 hours and a V_{dss} of 210 L (72% between-subject variability) in a 40-kg individual with a WBC count of $10^4/\mu\text{L}$, indicating extensive tissue distribution as observed in animal models. It was concluded that the pharmacokinetic parameters for clofarabine are proportional to the dose with no indication of a decline in intracellular triphosphate concentration with time [64].

The total binding of clofarabine to plasma protein amounts to 47%, and only 27% is bound to human serum albumin (HSA), which could be a factor in producing a wide tissue distribution [65].

When given to male and female patients with ALL or AML, clofarabine exhibits balanced clearance, with a renal clearance of 10.8 L/h/m^2 (28.8 L/h/m^2 total systemic clearance) with 57% of the dose being excreted unchanged in the urine [36]. The pharmacokinetics of clofarabine were further examined in 52 adults with solid tumors involved in a dose-escalation phase I study with doses up to 129 mg/m^2 administered once a week for 3 weeks every 28 days [66]. It was shown to be time-invariant, with an average systemic clearance, V_{dss} , and half-life of 18.1 L per h (9.9 L/h/m^2), 72 L (39 L/m^2) and 4.0 h , respectively. It was also observed during this study that, although clofarabine is a purine analog (as is fludarabine), its effects on lymphocyte subsets more closely resemble those of gemcitabine, a pyrimidine analog, in having a selective detrimental effect on the B-lymphocyte

subset [66]. This observation should be considered when developing appropriate combination regimens involving clofarabine.

Under the Biopharmaceutics Classification System, clofarabine is classified as a Class III drug. This classification is based on the fact that the adult clearance is ~20 L/h while oral bioavailability is ~50% with a mean absorption time of 2.0 hours (in adult patients with advanced solid tumors) [56].

4. Clinical studies

To date, numerous clinical studies on clofarabine have been conducted and some with promising results. A wide variability in responses among the patient populations has been observed, indicating the complexity of factors that need to be considered before administering clofarabine [67].

In the phase I trial the maximum tolerated dose (MTD) for patients with solid tumors was determined at 2 mg/m² with the dose limiting toxicity (DLT) consisting in myelosuppression, while for patients with hematological malignancies, the MTD was determined at 40 mg/m²/day with the DLT being hepatotoxicity [67]. This discrepancy is explained by the accepted view that drugs for leukemia cause myelosuppression and cytopenias of limited duration and thus are not regarded as dose-limiting conditions.

1
2 A phase II study in 62 adult patients with relapsed or refractory acute
3 leukemia and myelodysplastic syndrome who received clofarabine at 40 mg/m²
4
5 IV once daily for 5 days every 3 to 6 weeks demonstrated a total response rate of
6
7 48% [68]. After the first clofarabine infusion, responders accumulated more
8
9 clofarabine triphosphate in blasts than non-responders. This increased only in
10
11 responders after the second clofarabine infusion, indicating that cellular
12
13 pharmacokinetics may have prognostic significance. However, another phase II
14
15 trial in adult AML patients demonstrated a minimal response, most likely due to
16
17 the fact that the patients were significantly more refractory [69].
18
19
20
21
22
23
24
25
26

27 Clofarabine showed promising results in a phase II trial in elderly
28
29 refractory AML patients at doses of 30 mg/m²/day for 5 days every 28–42 days
30
31 with almost 50% of responders (40–50% CR) [70]. In particular, this agent
32
33 appears to be effective for patients with adverse cytogenetics, with an associated
34
35 remission rate of approximately 40%. If this finding is validated in further
36
37 studies, this is an interesting and beneficial feature.
38
39
40
41
42

43 In the phase I trial involving pediatric patients with ALL and AML, the
44
45 MTD was determined to be 52 mg/m² and the recommended phase II dose [62].
46
47 The DLT was reversible hepatotoxicity and skin rash. A total response of 30%
48
49 was observed in phase II trials in pediatric patients suffering from refractory
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

AML and ALL treated with clofarabine at doses of 52 mg/m²/day for 5 days every 2–6 weeks [63].

Most studies to date show the benefit of oral high-dose treatment with clofarabine. However, it is of interest to establish a low-dose regimen of clofarabine in tablet form when given during a longer period of treatment.

The promising *in vitro* data and results from animal studies led to the development of combination treatments with clofarabine and other cytotoxic agents. In this context, a human study involving treatment with clofarabine (30–40 mg/m²/day) in combination with AraC (20-100 mg/m²/day) in order to enhance dCK activity, was undertaken and was found to be more effective in previously untreated patients with AML and MDS than single agent treatment with comparable toxicity [71, 72].

Another phase I study on elderly AML patients has revealed that clofarabine, in combination with idarubicine and AraC, can lead to clinical remission. Anthracyclines are commonly used to potentiate the activity of other nucleoside analogues, with idarubicin being the preferred anthracycline in induction and salvage regimens of patients with AML. The response to combinations of clofarabine with AraC, clofarabine with idarubicin, and clofarabine plus AraC and idarubicine in AML salvage studies were not significantly different with a total response of 39% (CR+CRp) [73].

1
2 A pilot phase I study was conducted on 13 patients with AML and ALL
3
4 being treated with clofarabine in combination with cyclophosphamide and
5
6 etoposide to determine the MTD and the dose-limiting toxicities of the
7
8 combination [74]. This combination induced durable remission in children with
9
10 relapsed or refractory acute leukemia. The recommended phase II doses of
11
12 clofarabine, cyclophosphamide, and etoposide were 40 mg/m²/day, 440
13
14 mg/m²/day, and 100 mg/m²/day, respectively, each given for 5 days in induction.
15
16
17
18
19
20
21 The phase II portion of the study is now underway.
22
23

24 Treatment with 4-hydroperoxy-cyclophosphamide, an activated form of
25
26 cytoxan, induces DNA repair patches, thus increasing the incorporation of
27
28 clofarabine triphosphates into DNA and consequently enhances the cytotoxic effect
29
30 [44]. Conversely, the use of clofarabine prior to cyclophosphamide appeared to
31
32 augment both cyclophosphamide-induced DNA damage (by phosphorylated
33
34 H2AX) and apoptosis (by sub-2N DNA) [75].
35
36
37
38
39
40

41 In a phase I/II trial, clofarabine was given in combination with a
42
43 myeloablative dose of busulfan, an alkylating antineoplastic agent, in an attempt to
44
45 develop a pre-transplant conditioning regimen suitable for patients with refractory,
46
47 non-remissive hematologic malignancies at the time of transplant. As a result, all
48
49 20 patients engrafted rapidly, and this combination shows promising anti-tumor
50
51 activity in this group of very high-risk patients [76].
52
53
54
55
56
57
58
59
60
61
62
63
64
65

In summary, the MTD in patients with solid tumors is 20 times lower than in patients with hematological malignancies due to much lower non-hematopoietic toxicity than the prominent myelosuppression, which is the most common adverse affect in the case of solid tumors, whereas hepatotoxicity seems to be dose-limiting in patients with acute leukemias. Clofarabine plasma concentrations were generally lower in the pediatric population than in the adult population when the same doses were administered [36]. Although it is currently approved only for pediatric patients, clofarabine showed promising results in usually unresponsive elderly patients. Furthermore, clinical data show that combination regimens are feasible, but the optimal regimen for clofarabine combined with other anti-cancer agents remains to be determined.

5. Conclusion

In a nutshell, clofarabine exhibits efficacy in hematologic malignancies such as ALL, AML, and myelodysplastic syndrome. Like cladribine and fludarabine, clofarabine is toxic to both non-proliferating human lymphocytes and rapidly proliferating cells, while being resistant to phosphorylitic cleavage and deamination and stable in acidic environments. It exhibits the highest lipophilicity among related purine analogues [13] and is resistant to degradation by *E. coli*

nucleoside phosphorylase [14]. Clofarabine's high affinity for nucleoside transporters, dCK, and key enzymes involved in DNA synthesis, as well as the prolonged intracellular retention of its metabolites, contributes to its potent anti-cancer activity.

In clinical trials clofarabine shows the potential in the group with the poorest prognosis: older patients and those with adverse cytogenetics. It has also been shown to be active both as a single agent and in combination with other cytotoxic drugs. Although clofarabine acts as a myelosuppressive agent, its toxicity profile makes the drug potentially useful for patients excluded from intensive chemotherapy at diagnosis or who have relapsed after CR.

The process of approving a drug is often a very long and grueling procedure. Taking this into consideration and the fact that clofarabine has already been approved for the treatment of pediatric ALL with a second or higher relapse, new promising treatments with clofarabine could be implemented at an accelerated rate. Therefore, there is an urgent need to evaluate more thoroughly its potential in treating cancer. More recent clinical trials indicate that this drug has a broad-spectrum impact on a variety of leukemias, a unique property with a substantial potential for wider application.

The toxicities connected with clofarabine administration are manageable, thus allowing this drug to be combined effectively with other chemotherapeutic

agents. However, an exact understanding of the clofarabine mechanism of action remains to be achieved, making it difficult to explain the broad-spectrum distribution of responses to this drug in ongoing clinical trials. Although the clinical data suggest a higher efficacy of clofarabine in hematological malignancies, the *in vitro* anti-angiogenesis activity [77] can prove the drug useful for treatment of solid tumors.

Acknowledgments

Grant support: The Children Cancer Foundation, the Cancer and Allergy Foundation, the Cancer Society in Stockholm, the King Gustaf V Jubilee Fund, the Swedish Medical Society, the Swedish Cancer Foundation, the Swedish Research Council, the Göran Gustafsson Foundation for Research in Natural Sciences and Medicine, and the Karolinska Institute Foundations

Fig. 1 Structural formulas of deoxyadenosine (dAdo) and its analogues: cladribine, fludarabine phosphate, and clofarabine.

Fig. 2. Clofarabine's mechanism of action. Clofarabine is transported into the cell by either passive diffusion or facilitated/active transport by concentrative and equilibrative nucleoside transporters (ENTs and CNTs); in addition, there is some evidence of mitochondrial transport [16]. Upon entering the cell, clofarabine is phosphorylated stepwise by deoxycytidine kinase (dCK), monophosphate kinase (MPkinase), and diphosphate kinase (DPkinase) to its triphosphate active form (clofarabineTP). ClofarabineTP acts as an inhibitor of DNA polymerase- α (DNA pol α) and - ϵ (DNA pol ϵ) by competing with the natural substrate dATP. When incorporated into DNA, clofarabine leads to DNA damage, which signals activation of apoptotic pathways. It can further inhibit ribonucleotide reductase (RR), causing dNTP pool reduction and thus reinforcing its own incorporation into DNA. By directly affecting the mitochondrial transmembrane potential, clofarabine releases cytochrome c and apoptosis-inducing factor (AIF) [30]. In addition, it binds cytosolic apoptotic protease-activating factor 1 (APAF-1) and thus mediates caspase activation [30]. Consequently, caspase 9,

1 together with other pro-apoptotic factors, forms apoptosome, leading to cell
2
3
4
5 apoptosis. Moreover, clofarabine may mediate pro-apoptotic signals by
6
7
8 inducing down-regulation the death suppressor proteins Bcl-X_L and Mcl-1
9
10
11 and dephosphorylation of the anti-apoptotic kinase Akt [31].
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 REFERENCES 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65

- [1] Fox M, Boyle JM, Kinsella AR. Nucleoside salvage and resistance to antimetabolite anticancer agents. *Br J Cancer* 1991;64:428-36.
- [2] Mackey JR, Baldwin SA, Young JD, Cass CE. Nucleoside transport and its significance for anticancer drug resistance. *Drug Resist Updat* 1998;1:310-24.
- [3] Tallman MS. New agents for the treatment of acute myeloid leukemia. *Best Pract Res Clin Haematol* 2006;19:311-20.
- [4] Gale RP, Cline MJ. High remission-induction rate in acute myeloid leukaemia. *Lancet* 1977;1:497-9.
- [5] LePage GA, Khaliq A, Gottlieb JA. Studies of 9-beta-D-arabinofuranosyladenine in man. *Drug Metab Dispos* 1973;1:756-9.
- [6] Montgomery JA, Hewson K. Nucleosides of 2-fluoroadenine. *J Med Chem* 1969;12:498-504.
- [7] Struck RF, Shortnacy AT, Kirk MC, Thorpe MC, Brockman RW, Hill DL, et al. Identification of metabolites of 9-beta-D-arabinofuranosyl-2-fluoroadenine, an antitumor and antiviral agent. *Biochem Pharmacol* 1982;31:1975-8.
- [8] Christensen LF, Broom AD, Robins MJ, Bloch A. Synthesis and biological activity of selected 2,6-disubstituted-(2-deoxy- -and- -D-erythro-pentofuranosyl)purines. *J Med Chem* 1972;15:735-9.

- [9] Albertioni F, Juliusson G, Liliemark J. On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole. *Eur J Clin Pharmacol* 1993;44:579-82.
- [10] Liliemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. *J Clin Oncol* 1992;10:1514-8.
- [11] Lindemalm S, Liliemark J, Juliusson G, Larsson R, Albertioni F. Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia. *Cancer Lett* 2004;210:171-7.
- [12] Montgomery JA, Shortnacy-Fowler AT, Clayton SD, Riordan JM, Secrist JA, 3rd. Synthesis and biologic activity of 2'-fluoro-2'-halo derivatives of 9-beta-D-arabinofuranosyladenine. *J Med Chem* 1992;35:397-401.
- [13] Reichelova V, Liliemark J, Albertioni F. Liquid chromatographic study of acid stability of 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, 2-chloro-2'-deoxyadenosine and related analogues. *J Pharm Biomed Anal* 1995;13:711-4.
- [14] Carson DA, Wasson DB, Esparza LM, Carrera CJ, Kipps TJ, Cottam HB. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine. *Proc Natl Acad Sci U S A* 1992;89:2970-4.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
 - 61
 - 62
 - 63
 - 64
 - 65
- [15] Xie C, Plunkett W. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)-adenine in human lymphoblastoid cells. *Cancer Res* 1995;55:2847-52.
- [16] King KM, Damaraju VL, Vickers MF, Yao SY, Lang T, Tackaberry TE, et al. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. *Mol Pharmacol* 2006;69:346-53.
- [17] Sjoberg AH, Wang L, Eriksson S. Substrate specificity of human recombinant mitochondrial deoxyguanosine kinase with cytostatic and antiviral purine and pyrimidine analogs. *Mol Pharmacol* 1998;53:270-3.
- [18] Fyrberg A, Albertioni F, Lotfi K. Cell cycle effect on the activity of deoxynucleoside analogue metabolising enzymes. *Biochem Biophys Res Commun* 2007;357:847-53.
- [19] Eriksson S, Arner E, Spasokoukotskaja T, Wang L, Karlsson A, Brosjo O, et al. Properties and levels of deoxynucleoside kinases in normal and tumor cells; implications for chemotherapy. *Adv Enzyme Regul* 1994;34:13-25.
- [20] Lotfi K, Mansson E, Spasokoukotskaja T, Pettersson B, Liliemark J, Peterson C, et al. Biochemical pharmacology and resistance to 2-chloro-2'-

- 1
2 arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human
3
4
5 leukemic cells. Clin Cancer Res 1999;5:2438-44.
6
- 7
8 [21] Parker WB, Shaddix SC, Rose LM, Shewach DS, Hertel LW, Secrist JA,
9
10 3rd, et al. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-
11
12 deoxy-2- fluoro-beta-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-
13
14 fluoro- beta-D-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro-
15
16 beta-D-ribofuranosyl)adenine in CEM cells. Mol Pharmacol 1999;55:515-
17
18
19
20
21 20.
22
23
- 24 [22] Zhang Y, Secrist JA, 3rd, Ealick SE. The structure of human deoxycytidine
25
26
27 kinase in complex with clofarabine reveals key interactions for prodrug
28
29
30 activation. Acta Crystallogr D Biol Crystallogr 2006;62:133-9.
31
- 32 [23] Albertioni F, Lindemalm S, Reichelova V, Pettersson B, Eriksson S,
33
34
35 Juliusson G, et al. Pharmacokinetics of cladribine in plasma and its 5'-
36
37
38 monophosphate and 5'-triphosphate in leukemic cells of patients with
39
40
41 chronic lymphocytic leukemia. Clin Cancer Res 1998;4:653-8.
42
- 43 [24] Parker WB, Shaddix SC, Chang CH, White EL, Rose LM, Brockman RW,
44
45
46 et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-
47
48
49 arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of
50
51
52 human ribonucleotide reductase and DNA polymerases by its 5'-
53
54
55 triphosphate. Cancer Res 1991;51:2386-94.
56
57
58
59
60
61
62
63
64
65

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
 - 61
 - 62
 - 63
 - 64
 - 65
- [25] Xie KC, Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine. *Cancer Res* 1996;56:3030-7.
- [26] Chen LS, Plunkett W, Gandhi V. Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues. *Leuk Res* 2008;32:1573-81.
- [27] Chang CH, Cheng YC. Effects of deoxyadenosine triphosphate and 9-beta-D-arabinofuranosyl-adenine 5'-triphosphate on human ribonucleotide reductase from Molt-4F cells and the concept of "self-potential". *Cancer Res* 1980;40:3555-8.
- [28] Genini D, Budihardjo I, Plunkett W, Wang X, Carrera CJ, Cottam HB, et al. Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway. *J Biol Chem* 2000;275:29-34.
- [29] Leoni LM, Chao Q, Cottam HB, Genini D, Rosenbach M, Carrera CJ, et al. Induction of an apoptotic program in cell-free extracts by 2-chloro-2'-deoxyadenosine 5'-triphosphate and cytochrome c. *Proc Natl Acad Sci U S A* 1998;95:9567-71.
- [30] Genini D, Adachi S, Chao Q, Rose DW, Carrera CJ, Cottam HB, et al. Deoxyadenosine analogs induce programmed cell death in chronic

- lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. *Blood* 2000;96:3537-43.
- [31] Takahashi T, Shimizu M, Akinaga S. Mechanisms of the apoptotic activity of Cl-F-araA in a human T-ALL cell line, CCRF-CEM. *Cancer Chemother Pharmacol* 2002;50:193-201.
- [32] Mansson E, Flordal E, Liliemark J, Spasokoukotskaja T, Elford H, Lagercrantz S, et al. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. *Biochem Pharmacol* 2003;65:237-47.
- [33] Leegwater PA, De Abreu RA, Albertioni F. Analysis of DNA methylation of the 5' region of the deoxycytidine kinase gene in CCRF-CEM-sensitive and cladribine (CdA)- and 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine (CAFdA)-resistant cells. *Cancer Lett* 1998;130:169-73.
- [34] Chandra J, Mansson E, Gogvadze V, Kaufmann SH, Albertioni F, Orrenius S. Resistance of leukemic cells to 2-chlorodeoxyadenosine is due to a lack of calcium-dependent cytochrome c release. *Blood* 2002;99:655-63.
- [35] Waud WR, Schmid SM, Montgomery JA, Secrist JA, 3rd. Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-

- 1
2 arabinofuranosyl)adenine (Cl-F-ara-A). Nucleosides Nucleotides Nucleic
3
4
5 Acids 2000;19:447-60.
6
- 7
8 [36] Bonate PL, Arthaud L, Cantrell WR, Jr., Stephenson K, Secrist JA, 3rd,
9
10 Weitman S. Discovery and development of clofarabine: a nucleoside
11
12 analogue for treating cancer. Nat Rev Drug Discov 2006;5:855-63.
13
14
- 15
16 [37] Cariveau MJ, Stackhouse M, Cui XL, Tiwari K, Waud W, Secrist JA, 3rd, et
17
18 al. Clofarabine acts as radiosensitizer in vitro and in vivo by interfering with
19
20 DNA damage response. Int J Radiat Oncol Biol Phys 2008;70:213-20.
21
22
- 23
24 [38] Lee M, Tang X, Yang C, Cui X, Comeaux E, Allan P, et al. ATM
25
26 phosphorylation of deoxycytidine kinase is required for the synergism of
27
28 radiotherapy and nucleoside analogues. Abstract Number: 3980. Proceedings
29
30 of the 100th Annual Meeting of the AACR. Denver, CO, USA, 2009.
31
32
- 33
34 [39] Lindemalm S, Liliemark J, Gruber A, Eriksson S, Karlsson MO, Wang Y, et
35
36 al. Comparison of cytotoxicity of 2-chloro- 2'-arabino-fluoro-2'-
37
38 deoxyadenosine (clofarabine) with cladribine in mononuclear cells from
39
40 patients with acute myeloid and chronic lymphocytic leukemia.
41
42 Haematologica 2003;88:324-32.
43
44
- 45
46 [40] Albertioni F, Hassan M, Silberring J, Liliemark J. Kinetics and metabolism
47
48 of 2-chloro-2'-deoxyadenosine and 2-chloro-2'-arabino-fluoro-2'-
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- deoxyadenosine in the isolated perfused rat liver. *Eur J Drug Metab Pharmacokinet* 1995;20:225-32.
- [41] Elwi AN, Damaraju VL, Kuzma ML, Mowles DA, Baldwin SA, Young JD, et al. Transepithelial fluxes of adenosine and 2'-deoxyadenosine across human renal proximal tubule cells: roles of nucleoside transporters hENT1, hENT2, and hCNT3. *Am J Physiol Renal Physiol* 2009;296:F1439-51.
- [42] Bonate PL, Arthaud L, Stuhler J, Yerino P, Press RJ, Rose JQ. The distribution, metabolism, and elimination of clofarabine in rats. *Drug Metab Dispos* 2005;33:739-48.
- [43] Beesley AH, Palmer ML, Ford J, Weller RE, Cummings AJ, Freitas JR, et al. In vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia. *Br J Haematol* 2007;137:109-16.
- [44] Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. *Clin Cancer Res* 2001;7:3580-9.
- [45] Spasokoukotskaja T, Sasvari-Szekely M, Hullan L, Albertioni F, Eriksson S, Staub M. Activation of deoxycytidine kinase by various nucleoside analogues. *Adv Exp Med Biol* 1998;431:641-5.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
 - 61
 - 62
 - 63
 - 64
 - 65
- [46] Cooper T, Ayres M, Nowak B, Gandhi V. Biochemical modulation of cytarabine triphosphate by clofarabine. *Cancer Chemother Pharmacol* 2005;55:361-8.
- [47] Parker WB, Shaddix SC, Gilbert KS, Shepherd RV, Waud WR. Enhancement of the in vivo antitumor activity of clofarabine by 1-beta-D: -[4-thio-arabinofuranosyl]-cytosine. *Cancer Chemother Pharmacol* 2008.
- [48] Xie C, Edwards H, LoGrasso BS, Stout ML, Buck SA, Taub JW, et al. Valproic acid synergistically enhances clofarabine cytotoxicity in pediatric acute myeloid leukemia. Abstract Number: 4061. Proceedings of the 100th Annual Meeting of the AACR. Denver, CO, USA, 2009.
- [49] Zhang Y, Shahriar M, Zhang J, Ahmed SU, Lim SH. Clofarabine induces hypomethylation of DNA and expression of Cancer-Testis antigens. *Leuk Res* 2009.
- [50] Albertioni F, Mirzaee S, Wrabel A, Eriksson S, Lotfi K. Gene silencing of cytosolic 5,3-dNT (cNT1) induces apoptosis in leukemic cells in response to purine and pyrimidine nucleoside analogues. Abstract Number: 5451. . Proceedings of the 100th Annual Meeting of the AACR. Denver, CO, USA, 2009.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
 - 61
 - 62
 - 63
 - 64
 - 65
- [51] Stephenson K, al. e. Correlation between frequency of administration and efficacy of clofarabine in the H460 human non-small cell lung tumor xenograft model. *Proceedings of AACR* 2003;44:A814.
- [52] Lindemalm S, Liliemark J, Larsson BS, Albertioni F. Distribution of 2-chloro-2'-deoxyadenosine, 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, fludarabine and cytarabine in mice: a whole-body autoradiography study. *Med Oncol* 1999;16:239-44.
- [53] Berg SL, Bonate PL, Nuchtern JG, Dauser R, McGuffey L, Bernacky B, et al. Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates. *Clin Cancer Res* 2005;11:5981-3.
- [54] Takahashi T, Kanazawa J, Akinaga S, Tamaoki T, Okabe M. Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration. *Cancer Chemother Pharmacol* 1999;43:233-40.
- [55] Qian M, Wang X, Shanmuganathan K, Chu CK, Gallo JM. Pharmacokinetics of the anticancer agent 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine in rats. *Cancer Chemother Pharmacol* 1994;33:484-8.
- [56] Genzyme Corporation SA, TX. Clofarabine Investigator's Brochure. 2007.

- [57] Mt Vernon IBE. A five-day intravenous, a five-day oral, and a 21-day oral comparative hematological toxicity study of clofarabine in male Fischer 344 rats. 2007.
- [58] Heckl-Östreicher G, Müller C, Lutz C, Kulke M, Obermeier J, Minchinton A, et al. The use of the nucleoside-prodrug EPD-clofarabine (HDP15.0022) in different xenograft models of solid tumors. Abstract Number: 4523. Proceedings of the 100th Annual Meeting of the AACR. Denver, CO, USA, 2009.
- [59] Obermeier J, Heckl-Östreicher G, Müller C, Kulke M, Lutz C, Wehr R, et al. Antitumor activity of HDP15.0022, a novel orally active nucleoside derivative, in pancreatic xenograft models. Abstract Number: 4522. Proceedings of the 100th Annual Meeting of the AACR. Denver, CO, USA, 2009.
- [60] Gandhi V, Kantarjian H, Faderl S, Bonate P, Du M, Ayres M, et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res 2003;9:6335-42.
- [61] Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S. Clofarabine: past, present, and future. Leuk Lymphoma 2007;48:1922-30.

- [62] Jeha S, Gandhi V, Chan KW, McDonald L, Ramirez I, Madden R, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. *Blood* 2004;103:784-9.
- [63] Jeha S, Gaynon PS, Razzouk BI, Franklin J, Kadota R, Shen V, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. *J Clin Oncol* 2006;24:1917-23.
- [64] Bonate PL, Craig A, Gaynon P, Gandhi V, Jeha S, Kadota R, et al. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. *J Clin Pharmacol* 2004;44:1309-22.
- [65] Reichelova V, Juliusson G, Spasokoukotskaja T, Eriksson S, Liliemark J. Interspecies differences in the kinetic properties of deoxycytidine kinase elucidate the poor utility of a phase I pharmacologically directed dose-escalation concept for 2-chloro-2'-deoxyadenosine. *Cancer Chemother Pharmacol* 1995;36:524-9.
- [66] Cunningham C, J. Nemunaitis, N. Senzer, D. Richards, S. Vukelja, R. Abichandani, M. Vasconcelles. Effect of clofarabine on lymphocyte populations in patients treated for solid tumors. . *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I, 2007. p. 21134.

- [67] Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. *J Clin Oncol* 2003;21:1167-73.
- [68] Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. *Blood* 2003;102:2379-86.
- [69] Foran JM FS, Wetzler M, et al. A phase II, open-label study of clofarabine in adult patients with refractory or relapsed acute myelogenous leukemia ASCO: ASCO Proceedings, 2003. p. 587a.
- [70] Burnett AK, Mohite U. Treatment of older patients with acute myeloid leukemia--new agents. *Semin Hematol* 2006;43:96-106.
- [71] Faderl S, Gandhi V, Keating MJ, Jeha S, Plunkett W, Kantarjian HM. The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog. *Cancer* 2005;103:1985-95.
- [72] Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. *Blood* 2008;112:1638-45.

- [73] Faderl S, Borthakur G, Ravandi F, Huang X, Beran M, Ferrajoli A, et al. Results of a Randomized Phase 2 Study of Clofarabine Plus Cytarabine (CA) Vs Clofarabine Plus Idarubicin (CI) Vs Clofarabine, Idarubicin, Plus Cytarabine (CIA) as Salvage Therapy in Acute Myeloid Leukemia (AML) ASH Annual Meeting Abstracts 2008;50:Poster Board I-69.
- [74] Hijiya N, Gaynon PS, Fernandez M, Silverman LB, Thomson B, Chu R, et al. Durable Remissions Observed in a Phase I/II Study of Clofarabine in Combination with Etoposide and Cyclophosphamide in Pediatric Patients with Refractory or Relapsed Acute Leukemia ASH Annual Meeting and Exposition. San Francisco, CA, 2008. p. Poster Board III-7.
- [75] Karp JE, Ricklis RM, Balakrishnan K, Briel J, Greer J, Gore SD, et al. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 2007;110:1762-9.
- [76] Mineishi S, Magenau J, Pawarode A, Buck T, Jones DR, Kato K, et al. Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML. ASH Annual Meeting Abstracts 2008;50:Poster Board II-244.

- [77] Roy AM, Li R, Qu Z. Antiangiogenic activity of clofarabine. AACR Meeting Abstracts 2006;2006:55-c-6.

FIGURE 1

FIGURE 2

Clofarabine's mechanism of action. Upon entering the cell, clofarabine is phosphorylated stepwise by deoxycytidine kinase (dCK), monophosphate kinase (MPkinase), and diphosphate kinase (DPkinase) to its triphosphate active form (clofarabineTP). ClofarabineTP acts as an inhibitor of DNA polymerase- α (DNA pol α) and - ϵ (DNA pol ϵ) by competing with the natural substrate dATP. When incorporated into DNA, clofarabine leads to DNA damage, which signals activation of apoptotic pathways. It can further inhibit ribonucleotide reductase (RR), causing dNTP pool reduction and thus reinforcing its own incorporation into DNA. By directly affecting the mitochondrial transmembrane potential, clofarabine releases cytochrome c and apoptosis-inducing factor (AIF).